BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 1.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -93.5% | 41,700 | -37.9% | 0.00% | – |
| Q2 2023 | $139 | -61.1% | 67,200 | -37.8% | 0.00% | – |
| Q1 2023 | $357 | +101.7% | 108,000 | 0.0% | 0.00% | – |
| Q4 2022 | $177 | -100.0% | 108,000 | 0.0% | 0.00% | – |
| Q3 2022 | $478,000 | +86.0% | 108,000 | +16.1% | 0.00% | – |
| Q2 2022 | $257,000 | -17.6% | 93,000 | 0.0% | 0.00% | – |
| Q1 2022 | $312,000 | -16.1% | 93,000 | 0.0% | 0.00% | – |
| Q4 2021 | $372,000 | +21.2% | 93,000 | 0.0% | 0.00% | – |
| Q3 2021 | $307,000 | -13.0% | 93,000 | 0.0% | 0.00% | – |
| Q2 2021 | $353,000 | -24.6% | 93,000 | -23.9% | 0.00% | – |
| Q1 2021 | $468,000 | +372.7% | 122,161 | +460.2% | 0.00% | – |
| Q4 2020 | $99,000 | -44.4% | 21,806 | +107.3% | 0.00% | – |
| Q3 2020 | $178,000 | – | 10,520 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 241,500 | $1,093,000 | 0.17% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 90,584 | $410,000 | 0.13% |
| EPIQ PARTNERS, LLC | 10,550 | $48,000 | 0.03% |
| Phoenix Holdings Ltd. | 173,683 | $799,000 | 0.02% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 5,500 | $25,000 | 0.02% |
| CFO4Life Group, LLC | 12,003 | $54,000 | 0.02% |
| HighPoint Advisor Group LLC | 15,733 | $115,000 | 0.01% |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 357,761 | $1,619,000 | 0.01% |
| Virtu Financial LLC | 24,484 | $111,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 93,902 | $435,000 | 0.01% |